secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001974640-26-000001
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee Therapeutics FY2025 net loss $255.8M; cash $902.9M; zumilokibart milestones
--------------------------------------------------------------------------------

- Net loss $255.8M (FY2024: $182.1M); R&D expense $214.7M (FY2024: $167.9M).
- Cash, equivalents and marketable securities $902.9M; runway into 2H 2028.
- APEX Phase 2 Part A 52-week AD data expected March 2026; Part B 16-week data Q2 2026.
- Phase 3 AD initiation planned 2H 2026; asthma and EoE trial details later in 2026.
- Phase 1b head-to-head APG279 vs DUPIXENT in AD interim data anticipated 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000197464026000001/0001974640-26-000001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000197464026000001/apge-20260302.htm
  HTML page:      https://secwatch.observer/filing/0001974640-26-000001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer